Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27873727 | 1.00 | PARP10 (0.40) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL1857350 | 1.00 | PARP10 (0.40) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL17190969 | 0.81 | PARP1 (0.41) | PARP10PARP11KDM4EMAPT | |
| SCHEMBL27873730 | 0.79 | SRD5A1 (0.39) | KDM4EMAPT | |
| SCHEMBL159742 | 0.79 | SRD5A1 (0.39) | KDM4EMAPT | |
| SCHEMBL7897372 | 0.79 | SRD5A1 (0.39) | KDM4EMAPT | |
| SCHEMBL7897504 | 0.79 | KDM4E (0.31) | KDM4EMAPT | |
| SCHEMBL7897374 | 0.77 | MAPT (0.35) | KDM4EMAPT | |
| SCHEMBL27873729 | 0.77 | MAPT (0.35) | KDM4EMAPT | |
| SCHEMBL158376 | 0.77 | MAPT (0.35) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| CN-102617464-A | fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor | ABBOTT LAB | 2012-08-01 | — | — | CN | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| CN-102459179-A | Pyridinone antagonists of alpha-4 integrins | ELAN PHARM INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2424841-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | Elan Pharmaceuticals Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| CN-101445501-A | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| CN-1835924-A | Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor | ABBOTT LAB (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | PARP10 1783/4885PARP11 800/4885PIM1 3253/4885 |
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | PARP10 1858/4885PARP11 2054/4885PIM1 3503/4885 |
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | TRPV1, TRPV3, TRPA1 | PARP10 1462/4885PARP11 1002/4885PIM1 4314/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | PARP10 1814/4885PARP11 785/4885PIM1 3001/4885 |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | TRPV1, TRPV3, TRPA1 | PARP10 1462/4885PARP11 1002/4885PIM1 4314/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | PARP10 1783/4885PARP11 800/4885PIM1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.